Bioactive three loop coil

• US 20010034531A1
• Filed: 04/06/2001
• Published: 10/25/2001
• Est. Priority Date: 11/10/1998
• Status: Active Grant

• Current Assignee: Stryker European Operations Holdings, LLC (Stryker Corporation)
• Original Assignee: Scimed Life Systems Incorporated (Boston Scientific Corporation)
• Inventors: Slaikeu, Paul C., Eder, Joseph C., Wallace, Michael P., Ho, Hanh, Abrams, Robert M., Teoh, Clifford, Quan, Kenneth W. Jr., Barry, James
• Granted Patent: US 6,723,112 B2
• Time in Patent Office: Days
• US Class Current: 606/151
• CPC Class Codes: A61B 17/12022 Occluding by internal devices, e.g. balloons or releasable wires plugging an opening in the wall of an organ A61B17/0057; occluders for the cervical canal A61F6/146; vas deferens occluders A61F6/20
• CPC Class Codes: A61B 17/12113 within an aneurysm
• CPC Class Codes: A61B 17/12145 having a pre-set deployed three-dimensional shape methods of manufacturing A61B2017/00526
• CPC Class Codes: A61B 17/1215 comprising additional materials, e.g. thrombogenic, having filaments, having fibers, being coated
• CPC Class Codes: A61B 17/12172 having a pre-set deployed three-dimensional shape methods of manufacturing A61B2017/00526
• CPC Class Codes: A61B 17/12177 comprising additional materials, e.g. thrombogenic, having filaments, having fibers or being coated
• CPC Class Codes: A61B 2017/12063 electrolytically detachable
• CPC Class Codes: A61F 2/0077 Special surfaces of prostheses, e.g. for improving ingrowth A61F2/30767 takes precedence
• CPC Class Codes: A61L 2300/412 Tissue-regenerating or healing or proliferative agents
• CPC Class Codes: A61L 2430/36 for embolization or occlusion, e.g. vaso-occlusive compositions or devices
• CPC Class Codes: A61L 31/044 Collagen
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 65/04 Polyxylenes
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

One aspect of the present invention pertains to an implantable medical device for at least partially obstructing a neck portion of a vascular aneurysm. The device includes an occlusion subassembly comprising a base section and at least one lateral protrusion fixedly attached to the base section. A therapeutic agent is disposed upon at least one portion of at least one lateral protrusion.

Claims

1. An implantable medical device for at least partially obstructing a neck portion of a vascular aneurysm, comprising:

an occlusion subassembly comprising a base section and at least one lateral protrusion fixedly attached to the base section;

a therapeutic agent disposed upon at least one portion of the occlusion subassembly.

2. The implantable medical device of

claim 1

, wherein the base section is a central tubular member.

3. The implantable medical device of

claim 1

, wherein the therapeutic agent is a bioactive material.

4. The implantable medical device of

claim 3

, wherein the bioactive material is a biologically absorbable suture material that encourages cell growth.

5. The implantable medical device of

claim 4

, wherein the biologically absorbable suture material is polylactic acid.

6. The implantable medical device of

claim 4

, wherein the biologically absorbable suture material is polyglycolic acid.

7. The implantable medical device of

claim 4

, wherein the biologically absorbable suture material is a mixture of polyglycolic acid and polylactic acid.

8. The implantable medical device of

claim 1

, wherein the implantable medical device is of a size and overall flexibility to lodge at the neck portion of the vascular aneurysm, and is deliverable through a tubular delivery device.

9. The implantable medical device of

claim 8

, wherein said at least one lateral protrusion extends from said base section and is adapted to extend into a sac portion of the vascular aneurysm.

10. The implantable medical device of

claim 8

, wherein said at least one lateral protrusion extends from said base section and is adapted to engage a wall of the neck portion of the vascular aneurysm.

11. The implantable medical device of

claim 8

, wherein said at least one lateral protrusion is at least one loop member having a plurality of ends fixedly attached to said base section.

12. The implantable medical device of

claim 8

, wherein said at least one lateral protrusion is a plurality of loop members that extend radially from the base section and include a plurality of ends that are fixedly attached to said base section.

13. The implantable medical device of

claim 12

, wherein the base section comprises an outer coil radially disposed around an inner coil, wherein the inner coil is fixedly secured within the outer coil, and wherein the plurality of ends are fixedly secured between the outer and inner coils, and wherein the inner coil is adapted to radially surround and fixedly secure a distal end of a pusher wire.

14. The implantable medical device of

claim 13

, wherein the therapeutic agent is further disposed on at least one portion of the outer coil.

15. The implantable medical device of

claim 14

, wherein the therapeutic agent is a bioactive material.

16. The implantable medical device of

claim 14

, wherein the therapeutic agent is further disposed on any exposed portions of the inner coil.

17. The implantable medical device of

claim 12

, wherein the therapeutic agent is a bioactive material.

18. The implantable medical device of

claim 17

, wherein the bioactive material is a biologically absorbable suture material that encourages cell growth.

19. The implantable medical device of

claim 18

, wherein the biologically absorbable suture material is polylactic acid.

20. The implantable medical device of

claim 18

, wherein the biologically absorbable suture material is polyglycolic acid.

21. The implantable medical device of

claim 18

, wherein the biologically absorbable suture material is a mixture of polyglycolic acid and polylactic acid.

22. The implantable medical device of

claim 18

, wherein the biologically absorbable suture material is further disposed upon at least one portion of the base section.

23. The implantable medical device of

claim 18

, wherein the biologically absorbable suture material is produced in a strand form and wrapped around at least one portion of at least one lateral protrusion.

24. The implantable medical device of

claim 18

, wherein the biologically absorbable suture material is produced in a strand form and braided around at least one portion of at least one lateral protrusion.

25. The implantable medical device of

claim 18

, wherein the biologically absorbable material is produced in a tubular form and slipped over at least one portion of the occlusion subassembly.

26. The implantable medical device of

claim 18

, wherein the biologically absorbable material is sprayed on at least one portion of the occlusion subassembly.

27. The implantable medical device of

claim 18

, wherein the biologically absorbable material is dip coated on at least one portion of at least one lateral protrusion.

28. The implantable medical device of

claim 22

, wherein the biologically absorbable material is sprayed on at least one portion of the base section and at least one portion of at least one lateral protrusion.

29. The implantable medical device of

claim 22

, wherein the biologically absorbable material is dip coated on at least one portion of the base section and at least one portion of at least one lateral protrusion.

30. An implantable retainer bridge, deliverable via a vascular catheter, of a size and overall flexibility to lodge at the neck of a vascular aneurysm, and suitable for retaining at least a vaso-occlusive device in a vascular aneurysm, comprising:

an elongated tubular delivery member having a proximal end and a distal end;

a vaso-occlusion device retainer subassembly comprising a base section, a plurality of loops having ends fixedly attached to said base section, said retainer subassembly having a first delivery shape when within said vascular catheter and a second deployed shape, different than the first delivery shape, when said retainer subassembly is not retained within said vascular catheter, said base section being positioned coaxially about and adjacent to the distal end of said elongate tubular delivery member, said base section being detachable from said elongated tubular member upon severance of an electrolytically severable joint;

said electrolytically severable joint being between said retainer subassembly and said elongated tubular delivery member, severable upon application of a suitable current to said joint; and

a therapeutic agent disposed upon at least one portion of at least one of the plurality of loops.

31. The implantable retainer bridge of

claim 30

, wherein the therapeutic agent is a bioactive material.

32. The implantable retainer bridge of

claim 31

, wherein the bioactive material is a biologically absorbable suture material that encourages cell growth.

33. The implantable retainer bridge of

claim 32

, wherein the biologically absorbable suture material is further disposed upon at least one portion of the base section.

34. The implantable retainer bridge of

claim 33

, wherein the biologically absorbable material is sprayed on at least one portion of the base section and at least one portion of at least one of the plurality of loops.

35. The implantable retainer bridge of

claim 33

, wherein the biologically absorbable material is dip coated on at least one portion of the base section and at least one portion of at least one of the plurality of loops.

36. An implantable retainer, deliverable via an elongate tubular delivery device, for retaining at least a vaso-occlusive device in a vascular aneurysm, comprising:

a core wire having a proximal end and a distal end;

a joint extending between the distal end of the core wire and at least one array element, said joint being electrolytically severable upon application of a suitable current to said joint, said joint being comparatively more susceptible to electrolytic severability than said core wire and said at least one array element;

a retainer assembly comprising said at least one array element, said retainer assembly having a first delivery shape when retained within said elongate tubular delivery device and a second deployed shape, different than the first delivery shape, when said retainer assembly is not retained within said tubular delivery device, said at least one array element extending outwardly from said joint in said second deployed shape, and wherein after an electrolytic severance from said core wire, said retainer assembly includes a residual joint; and

bioactive material disposed upon at least one portion of at least one array element.

37. The implantable retainer of

claim 36

, wherein the therapeutic agent is a bioactive material.

38. The implantable retainer of

claim 37

, wherein the bioactive material is a biologically absorbable suture material that encourages cell growth.

39. The implantable retainer of

claim 38

, wherein the biologically absorbable suture material is polylactic acid.

40. The implantable retainer of

claim 38

, wherein the biologically absorbable suture material is polyglycolic acid.

41. The implantable retainer of

claim 38

, wherein the biologically absorbable suture material is a mixture of polyglycolic acid and polylactic acid.